Your browser doesn't support javascript.
loading
Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients.
Jakobsen, Lasse H; Ellin, Fredrik; Smeland, Knut B; Wästerlid, Tove; Christensen, Jacob H; Jørgensen, Judit M; Josefsson, Pär L; Øvlisen, Andreas K; Holte, Harald; Blaker, Yngvild N; Grauslund, Jacob H; Bjørn, Jon; Molin, Daniel; Lagerlöf, Ingemar; Smedby, Karin E; Colvin, Katherine; Thanarajasingam, Gita; Maurer, Matthew J; Habermann, Thomas M; Song, Kevin W; Zhu, Katie Y; Gerrie, Alina S; Cheah, Chan Y; El-Galaly, Tarec C.
Afiliación
  • Jakobsen LH; Department of Hematology, Aalborg University Hospital, Aalborg, Denmark.
  • Ellin F; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
  • Smeland KB; Department of Clinical Sciences Lund, Oncology, Lund University, Lund, Sweden.
  • Wästerlid T; Department of Oncology, Oslo University Hospital, Oslo, Norway.
  • Christensen JH; Department of Medicine Solna, Division of Clinical Epidemiology, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Sweden.
  • Jørgensen JM; Department of Hematology, Odense University Hospital, Odense, Denmark.
  • Josefsson PL; Department of Hematology, Aarhus University Hospital, Aarhus, Denmark.
  • Øvlisen AK; Department of Hematology, Herlev Hospital, Herlev, Denmark.
  • Holte H; Department of Hematology, Aalborg University Hospital, Aalborg, Denmark.
  • Blaker YN; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
  • Grauslund JH; Department of Oncology, Oslo University Hospital, Oslo, Norway.
  • Bjørn J; KG Jebsen Centre for B-cell malignancies, Oslo, Norway.
  • Molin D; KG Jebsen Centre for B-cell malignancies, Oslo, Norway.
  • Lagerlöf I; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
  • Smedby KE; Department of Hematology, Roskilde Sygehus, Roskilde, Denmark.
  • Colvin K; Department of Hematology, Rigshospitalet, Copenhagen, Denmark.
  • Thanarajasingam G; Experimental and Clinical Oncology, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
  • Maurer MJ; Division of Drug Research, Department of Medical and Health Sciences, Linköping University, Linköping, Sweden.
  • Habermann TM; Department of Medicine Solna, Division of Clinical Epidemiology, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Sweden.
  • Song KW; Department of Haematology, Sir Charles Gairdner Hospital, Nedlands, WA, Australia.
  • Zhu KY; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
  • Gerrie AS; Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
  • Cheah CY; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
  • El-Galaly TC; Leukemia/BMT Program of BC, Centre for Lymphoid Cancer, BC Cancer, Vancouver, Canada.
Br J Haematol ; 189(4): 661-671, 2020 05.
Article en En | MEDLINE | ID: mdl-32017050
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Linfoma de Burkitt Tipo de estudio: Etiology_studies / Guideline / Observational_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Br J Haematol Año: 2020 Tipo del documento: Article País de afiliación: Dinamarca
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Linfoma de Burkitt Tipo de estudio: Etiology_studies / Guideline / Observational_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Br J Haematol Año: 2020 Tipo del documento: Article País de afiliación: Dinamarca